Oncosil Medical (OSL) Q2 2025 TU earnings summary

Executive summary

• Expanded global distribution with new agreements in GCC, Egypt, and Nordics, enhancing market reach for pancreatic cancer treatment device.

• Achieved key regulatory milestones, including UKCA renewal and MDR certification, streamlining EU and UK market access.

• Initiated first OncoSil treatment in Italy and began patient recruitment for the TRIPP-FFX trial in Australia, with 49 global enrollees.

• Substantial increase in sales and customer receipts, reflecting growing demand for the device.

Financial highlights

• Raised $8 million in new equity: $7 million via placement and $1 million through a Share Purchase Plan.

• Cash and equivalents at 31 December 2024 totaled $8.463 million, up from $4.001 million at 30 September 2024.

• Customer receipts for the quarter were $0.339 million, totaling $0.402 million for the half year, a 45% increase over FY2024 full year.

• Net cash used in operating activities for the quarter was $(2.976) million.

• Estimated quarters of funding available at current burn rate: 2.84.

Outlook and guidance

• Management is focused on commercialization in multiple markets, expecting continued revenue growth over the next 12 months.